Aligos Therapeutics, Inc. (ALGS): Net earnings per share growth forecast for next year

Corporate emblem and logo of Aligos (ALGS)

The virology market is oversaturated, creating risks for Aligos Therapeutics (ALGS) due to potential trial failures. The projected net income per share growth rate reflects current volatility, where 16.10 determines the latest valuation metric. Positive data on hepatitis B molecules support the share price, while a strategy focused on curing patients without lifelong therapy builds the company's long-term potential.

ALGS: Aligos Earnings growth forecast for next year 07/04/2022 - 11/14/2026

ALGS (Aligos Therapeutics, Inc.): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Stock Price Aligos Therapeutics Inc.|ALGS - Average Forecast Price
- stock exchange capitalization data:
Market Value Aligos Therapeutics|ALGS - Value Adjusted for Debt and Cash
- company book value details:
Book Value per Share Aligos Therapeutics|ALGS - Book Capitalization|Market Value to Book Value Ratio aligos.com|ALGS - Aggregate Company Assets
- company total debt and liquidity indicators:
Total Debt to Capital Aligos Therapeutics|ALGS - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Aligos Therapeutics Inc.|ALGS - Company Total Indebtedness|Debt to Book Capitalization Ratio Aligos Therapeutics|ALGS - Long-Term Debt|Company Short-Term Debt Aligos Therapeutics|Quick Liquidity Indicator aligos.com
- earnings and valuation multiples information:
ALGS - Final Profit|Future Profit Aligos Therapeutics|ALGS - Market Price to Net Income Ratio|Forward P/E Multiple Aligos Therapeutics Inc.|ALGS - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Aligos Therapeutics|ALGS - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Aligos Therapeutics|ALGS - Earnings per share for the trailing year|Quarterly EPS earnings growth aligos.com|ALGS - Earnings growth in current year|Net earnings per share growth forecast for next year Aligos Therapeutics
- revenue and sales proceeds data:
ALGS - Company Annual Revenue|Projected Sales Volume Aligos Therapeutics Inc.|ALGS - Price to Sales|Forward Price-to-Revenue Multiple Aligos Therapeutics
Analysis of all company metrics:ALGS, Aligos Therapeutics
Finished products of Aligos Therapeutics, Inc.

Amid market volatility, investors seek to minimize risk by searching for defensive assets. The narrow specialization of Aligos Therapeutics (ALGS) in hepatitis B therapy and metabolic liver pathologies reduces dependence on pricing wars, ensuring the stability of fundamental indicators. The trend in estimated net income per share growth for the coming year reflects analysts' revisions of operating expenses and debt load, allowing for an assessment of the business's scaling potential and capital resilience.

Competitors of Aligos Therapeutics

ARWR (Arrowhead Pharmaceuticals Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year Mirum Pharmaceuticals Inc MIRM|Net earnings per share growth forecast for next year Dynavax (DVAX)|ABUS (arbutusbio.com) - Expected earnings per share trend next year|Earnings growth forecast for next year IVA (Inventiva)|Earnings growth forecast for next year Gyre Therapeutics Inc GYRE|ASMB - Net earnings per share growth forecast for next year|GALT: Net earnings per share growth forecast for next year|GNFT: Earnings growth forecast for next year|DRRX - Consensus forecast of earnings per share growth for next year|BIVI (BioVie Inc) - Earnings growth forecast for next year|GLMD - Net earnings per one share growth forecast for next year|Net earnings per share growth forecast for next year ENDRA (NDRA)|HEPA - Expected net earnings per share growth next year